B-cell lymphoma 2 (BCL2) (BCL2)

B-cell lymphoma 2 (BCL2) is a critical anti-apoptotic protein that resides on the outer mitochondrial membrane and governs the intrinsic cell death pathway (UniProt: P10415). It acts by sequestering pro-apoptotic members of the BCL-2 family, thereby preventing the formation of pores in the mitochondrial membrane that would lead to apoptosis (PMID: 26739578). In various cancers, particularly B-cell malignancies like chronic lymphocytic leukemia and follicular lymphoma, BCL2 is frequently overexpressed, often as a result of the t(14;18) chromosomal translocation (NCI Thesaurus: C17354). This overexpression provides a survival advantage to malignant cells, allowing them to resist chemotherapy and other stressors. The therapeutic landscape was significantly altered by the introduction of venetoclax, a highly selective BCL2 inhibitor that effectively induces apoptosis in cancer cells (FDA: Venclexta). Clinical use of BCL2 inhibitors requires vigilance for tumor lysis syndrome, especially during the initiation of therapy in patients with high tumor burdens. Research continues into the role of BCL2 in other cancer types and the development of next-generation inhibitors to overcome resistance mechanisms. Note: The input name was flagged as incorrect because it refers to a broad category of targets rather than a single canonical entity.

Other names

Bcl-2Apoptosis regulator Bcl-2BCL2L1

BCL2 inhibitors function as BH3-mimetics that bind to the hydrophobic groove of the B-cell lymphoma 2 protein, displacing pro-apoptotic proteins such as BIM, which then trigger mitochondrial outer membrane permeabilization and subsequent apoptosis (PMID: 26739578).